Literature DB >> 18819023

National surveillance of antifungal susceptibility of Candida species in South Korean hospitals.

Jae Il Yoo1, Chi Won Choi, Kyeong Min Lee, Young Kwon Kim, Tae Un Kim, Eui-Chong Kim, Sae Ik Joo, Seon Han Yun, Yeong Seon Lee, Bong Su Kim.   

Abstract

We investigated the species distribution and antifungal susceptibility of Candida isolates from tertiary and non-tertiary hospitals in South Korea from 2002-2004. Of the 612 Candida isolates that were collected, Candida albicans, C. parapsilosis, C. tropicalis, and C. glabrata occurred most frequently, accounting for 97.3% and 96.8% of the isolates in tertiary and non-tertiary hospitals, respectively. C. albicans was the most common isolate, but the incidence of non-C. albicansCandida species was higher than that of C. albicans in tertiary hospitals. The Candida species had much lower MIC(90) to voriconazole (tertiary hospitals: 0.5 microg/ml, non-tertiary hospitals: 0.25 microg/ml) than to fluconazole (tertiary hospitals: 8 microg/ml, non-tertiary hospitals: 4 microg/ml). The MIC(90) of Candida isolates to 5-flucytosine in non-tertiary hospitals was two times higher than that observed in tertiary facilities. The C. glabrata isolates showed a tendency toward strong resistance to fluconazole, but C. parapsilosis isolates were susceptible to all of the evaluated antifungal agents. Voriconazole showed strong in vitro activity against Candida species, especially C. krusei, which is resistant to fluconazole and 5-flucytosine. To our knowledge, this is the first report of Candida antifungal susceptibility that includes non-tertiary hospitals in South Korea.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18819023     DOI: 10.1080/13693780802354037

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  8 in total

1.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; D Ellis; V Tullio; A Rodloff; W Fu; T A Ling
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

2.  Proteomic Analysis of Cellular and Membrane Proteins in Fluconazole-Resistant Candida glabrata.

Authors:  Jae Il Yoo; Chi Won Choi; Hwa Su Kim; Jung Sik Yoo; Young Hee Jeong; Yeong Seon Lee
Journal:  Osong Public Health Res Perspect       Date:  2012-06

3.  Determination of antifungal susceptibility patterns among the clinical isolates of Candida species.

Authors:  Kamiar Zomorodian; Mohammad Javad Rahimi; Kayvan Pakshir; Marjan Motamedi; Moosa Rahimi Ghiasi; Hasanein Rezashah
Journal:  J Glob Infect Dis       Date:  2011-10

Review 4.  Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.

Authors:  Sarah G Whaley; Elizabeth L Berkow; Jeffrey M Rybak; Andrew T Nishimoto; Katherine S Barker; P David Rogers
Journal:  Front Microbiol       Date:  2017-01-12       Impact factor: 5.640

5.  Protein kinase A governs growth and virulence in Candida tropicalis.

Authors:  Chi-Jan Lin; Chia-Yen Wu; Shang-Jie Yu; Ying-Lien Chen
Journal:  Virulence       Date:  2018-01-01       Impact factor: 5.882

6.  Prevalence and antifungal drug resistance of nosocomial Candida species isolated from two university hospitals in Egypt.

Authors:  Amira M El-Ganiny; Nehal E Yossef; Hend A Kamel
Journal:  Curr Med Mycol       Date:  2021-03

7.  Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical Candida albicans and non-albicans isolates.

Authors:  Amira M El-Ganiny; Hend A Kamel; Nehal E Yossef; Basem Mansour; Ahmed M El-Baz
Journal:  Saudi Pharm J       Date:  2022-01-19       Impact factor: 4.562

8.  Proteomic Analysis of Intracellular and Membrane Proteins From Voriconazole-Resistant Candida glabrata.

Authors:  Jae Il Yoo; Hwa Su Kim; Chi Won Choi; Jung Sik Yoo; Jae Yon Yu; Yeong Seon Lee
Journal:  Osong Public Health Res Perspect       Date:  2013-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.